Mast Cell Proteases as Protective and Inflammatory Mediators

  • George H. Caughey
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 716)


Proteases are the most abundant class of proteins produced by mast cells. Many of these are stored in membrane-enclosed intracellular granules until liberated by degranulating stimuli, which include cross-linking of high affinity IgE receptor FcεRI by IgE bound to multivalent allergen. Understanding and separating the functions of the proteases is important because expression differs among mast cells in different tissue locations. Differences between laboratory animals and humans in protease expression also influence the degree of confidence with which results obtained in animal models of mast cell function can be extrapolated to humans. The inflammatory potential of mast cell proteases was the first aspect of their biology to be explored and has received the most attention, in part because some of them, notably tryptases and chymases, are biomarkers of local and systemic mast cell degranulation and anaphylaxis. Although some of the proteases indeed augment allergic inflammation and are potential targets for inhibition to treat asthma and related allergic disorders, they are protective and even anti-inflammatory in some settings. For example, mast cell tryptases may protect from serious bacterial lung infections and may limit the “rubor” component of inflammation caused by vasodilating neuropeptides in the skin. Chymases help to maintain intestinal barrier function and to expel parasitic worms and may support blood pressure during anaphylaxis by generating angiotensin II. In other life-or-death examples, carboxypeptidase A3 and other mast cell peptidases limit systemic toxicity of endogenous peptideslike endothelin and neurotensin during septic peritonitis and inactivate venom-associated peptides. On the other hand, mast cell peptidase-mediated destruction of protective cytokines, like IL-6, can enhance mortality from sepsis. Peptidases released from mast cells also influence nonmast cell proteases, such as by activating matrix metalloproteinase cascades, which are important in responses to infection and resolution of tissue injury. Overall, mast cell proteases have a variety of roles, inflammatory and anti-inflammatory, protective and deleterious, in keeping with the increasingly well-appreciated contributions of mast cells in allergy, tissue homeostasis and innate immunity.


Mast Cell Human Mast Cell Tracheal Smooth Muscle Mast Cell Tryptase Nafamostat Mesilate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stevens RL, Adachi R. Protease-proteoglycan complexes of mouse and human mast cells and importance of their ß-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev 2007; 217:155–167.PubMedCrossRefGoogle Scholar
  2. 2.
    Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007; 217:141–154.PubMedCrossRefGoogle Scholar
  3. 3.
    Pejler G, Ronnberg E, Waern I et al. Mast cell proteases-multifaceted regulators of inflammatory disease. Blood 2010 [Epub ahead of print].Google Scholar
  4. 4.
    Trivedi NN, Caughey GH. Mast cell peptidases: Chameleons of innate immunity and host defense. Am J Respir Cell Mol Biol 2010; 42:257–267.PubMedCrossRefGoogle Scholar
  5. 5.
    Brain SD, Williams TJ. Substance P regulates the vasodilator activity of calcitonin gene-related peptide. Nature 1988; 335:73–75.PubMedCrossRefGoogle Scholar
  6. 6.
    Tarn EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 1990; 3:27–32.Google Scholar
  7. 7.
    Walls AF, Brain SD, Desai A et al. Human mast cell tryptase attenuates the vasodilator activity of calcitonin gene-related peptide. Biochem Pharmacol 1992; 43:1243–1248.PubMedCrossRefGoogle Scholar
  8. 8.
    Steinhoff M, Vergnolle N, Young SH et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6:151–158.PubMedCrossRefGoogle Scholar
  9. 9.
    Corvera CU, Dery O, McConalogue K et al. Mast cell tryptase regulates rat colonic myocytes through PAR-2. J Clin Invest 1997; 100:1383–1393.PubMedCrossRefGoogle Scholar
  10. 10.
    Molino M, Barnathan ES, Numerof R et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997; 272:4043–4049.PubMedCrossRefGoogle Scholar
  11. 11.
    Schmidlin F, Amadesi S, Vidil R et al. Expression and function of PAR-2 in human bronchial smooth muscle. Am J Respir Crit Care Med 2001; 164:1276–1281.PubMedGoogle Scholar
  12. 12.
    Steinhoff M, Corvera CU, Thoma MS et al. PAR-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 1999; 8:282–294.PubMedCrossRefGoogle Scholar
  13. 13.
    Compton SJ, Renaux B, Wijesuriya SJ et al. Glycosylation and the activation of PAR-2 by human mast cell tryptase. Br J Pharmacol 2001; 134:705–718.PubMedCrossRefGoogle Scholar
  14. 14.
    Cottrell GS, Amadesi S, Pikios S et al. PAR-2, dipeptidyl peptidase I and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology 2007; 132:2422–2437.PubMedCrossRefGoogle Scholar
  15. 15.
    Stead RH, Dixon MF, Bramwell NH et al. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 1989; 97:575–585.PubMedGoogle Scholar
  16. 16.
    Steinhoff M, Neisius U, Ikoma A et al. PrAR-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003; 23:6176–6180.PubMedGoogle Scholar
  17. 17.
    Ui H, Andoh T, Lee JB et al. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol 2006; 530:172–178.PubMedCrossRefGoogle Scholar
  18. 18.
    Cenac N, Andrews CN, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117:636–647.PubMedCrossRefGoogle Scholar
  19. 19.
    Sekizawa K, Caughey GH, Lazarus SC et al. Mast cell tryptase causes airway smooth muscle hyperresponsiveness in dogs. J Clin Invest 1989; 83:175–179.PubMedCrossRefGoogle Scholar
  20. 20.
    Johnson PRA, Ammit AJ, Carlin SM et al. Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus. Eur Resp J 1997; 10:38–43.CrossRefGoogle Scholar
  21. 21.
    Barrios VE, Middleton SC, Kashem MA et al. Tryptase mediates hyperresponsiveness in isolated guinea pig bronchi Life Sci 1998; 63:2295–2303.PubMedCrossRefGoogle Scholar
  22. 22.
    Berger P, Compton SJ, Molimard M et al. Mast cell tryptase as a mediator of hyperresponsiveness in human isolated bronchi. Clin Exp Allergy 1999; 29:804–812.PubMedCrossRefGoogle Scholar
  23. 23.
    Molinari JF, Scuri M, Moore WR et al. Inhaled tryptase causes bronchoconstriction in sheep via histamine release. Am J Respir Crit Care Med 1996; 154:649–653.PubMedGoogle Scholar
  24. 24.
    Cocks TM, Fong B, Chow JM et al. A protective role for protease-activated receptors in the airways. Nature 1999; 398:156–160.PubMedCrossRefGoogle Scholar
  25. 25.
    Caughey GH, Leidig F, Viro NF et al. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988; 244:133–137.PubMedGoogle Scholar
  26. 26.
    Franconi GM, Graf PD, Lazarus SC et al. Mast cell chymase and tryptase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J Pharmacol Exp Ther 1989; 248:947–951.PubMedGoogle Scholar
  27. 27.
    Tam EK, Franconi GM, Nadel JA et al. Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. Am J Respir Cell Mol Biol 1990; 2:449–452.PubMedGoogle Scholar
  28. 28.
    Gruber BL, Marchese MJ, Suzuki K et al. Synovial procollagenase activation by human mast cell tryptase. J Clin Invest 1989; 84:1657–1662.PubMedCrossRefGoogle Scholar
  29. 29.
    Kobayashi M, Kume H, Oguma T et al. Mast cell tryptase causes homologous desensitization of β-adrenoceptors by Ca2+ sensitization in tracheal smooth muscle. Clin Exp Allergy 2008; 38:135–144.PubMedGoogle Scholar
  30. 30.
    Piliponsky AM, Chen CC, Nishimura T et al. Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med 2008; 14:392–398.PubMedCrossRefGoogle Scholar
  31. 31.
    Maurer M, Wedemeyer J, Metz M et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004; 432:512–516.PubMedCrossRefGoogle Scholar
  32. 32.
    Schneider LA, Schlenner SM, Feyerabend TB et al. Molecular mechanism of mast cell mediated innate defense against endothelin and snake venom sarafotoxin. J Exp Med 2007; 204:2629–2639.PubMedCrossRefGoogle Scholar
  33. 33.
    Nakano A, Kishi F, Minami K et al. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997; 159:1987–1992.PubMedGoogle Scholar
  34. 34.
    Nagata N, Niwa Y, Nakaya Y. Anovel 31-amino-acid-length endothelin, ET-1(1–31), can act as abiologically active peptide for vascular smooth muscle cells. Biochem Biophys Res Commun 2000; 275:595–600.PubMedCrossRefGoogle Scholar
  35. 35.
    Nagase T, Kurihara H, Kurihara Y et al. Airway hyperresponsiveness to methacholine in mutant mice deficient in endothelin-1. Am J Respir Crit Care Med 1998; 157:560–564.PubMedGoogle Scholar
  36. 36.
    Irani AM, Goldstein SM, Wintroub BU et al. Human mast cell carboxypeptidase: Selective localization to MCTC cells. J Immunol 1991; 147:247–253.PubMedGoogle Scholar
  37. 37.
    Goldstein SM, Leong J, Schwartz LB et al. Protease composition of exocytosed human skin mast cell protease-proteoglycan complexes: tryptase resides in acomplex distinct from chymase and carboxypeptidase. J Immunol 1992; 148:2475–2482.PubMedGoogle Scholar
  38. 38.
    Dougherty RH, Sidhu SS, Raman K et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in Th2-high asthma. J Allergy Clin Immunol 2010; 125:1046–1053.PubMedCrossRefGoogle Scholar
  39. 39.
    Schiemann F, Brandt E, Gross R et al. The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4. J Immunol 2009; 183:2223–2231.PubMedCrossRefGoogle Scholar
  40. 40.
    Schiemann F, Grimm TA, Hoch J et al. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood 2006; 107:2234–2242.PubMedCrossRefGoogle Scholar
  41. 41.
    Zhao W, Oskeritzian CA, Pozez AL et al. Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. J Immunol 2005; 175:2635–2642.PubMedGoogle Scholar
  42. 42.
    Schechter NM, Sprows JL, Schoenberger OL et al. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem 1989; 264:21308–21315.PubMedGoogle Scholar
  43. 43.
    Walter M, Sutton RM, Schechter NM. Highly efficient inhibition of human chymase by α2-macroglobulin. Arch Biochem Biophys 1999; 368:276–284.PubMedCrossRefGoogle Scholar
  44. 44.
    Raymond WW, Su S, Makarova A et al. α2-Macroglobulin capture allows detection of mast cell chymase in serum and creates a reservoir of angiotensin II-generating activity. J Immunol 2009; 182:5770–5777.PubMedCrossRefGoogle Scholar
  45. 45.
    Mallen-St Clair J, Pham CT, Villalta SA et al. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 2004; 113:628–634.Google Scholar
  46. 46.
    Metz M, Piliponsky AM, Chen CC et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 2006; 313:526–530.PubMedCrossRefGoogle Scholar
  47. 47.
    Fang KC, Raymond WW, Lazarus SC et al. Dog mastocytoma cells secrete a 92-kd gelatinase activated extracellularly by mast cell chymase. J Clin Invest 1996; 97:1589–1596.PubMedCrossRefGoogle Scholar
  48. 48.
    Fang KC, Wolters PJ, Steinhoff M et al. Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-β. J Immunol 1999; 162:5528–5535.PubMedGoogle Scholar
  49. 49.
    Coussens LM, Raymond WW, Bergers G et al. Inflammatory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13:1382–1397.PubMedCrossRefGoogle Scholar
  50. 50.
    Baram D, Vaday GG, Salamon P et al. Human mast cells release metalloproteinase-9 on contact with activated T-cells: juxtacrine regulation by TNFα. J Immunol 2001; 167:4008–4016.PubMedGoogle Scholar
  51. 51.
    Tchougounova E, Lundequist A, Fajardo I et al. A key role for mast cell chymase in the activation of proMMP-9 and proMMP-2. J Biol Chem 2005; 280:9291–9296.PubMedCrossRefGoogle Scholar
  52. 52.
    McQuibban GA, Gong JH, Tam EM et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289:1202–1206.PubMedCrossRefGoogle Scholar
  53. 53.
    Greenlee KJ, Corry DB, Engler DA et al. Proteomic identification of in vivo substrates for MMPs 2 and 9 reveals a mechanism for resolution of inflammation. J Immunol 2006; 177:7312–7321.PubMedGoogle Scholar
  54. 54.
    Vu TH, Shipley JM, Bergers G et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93:411–422.PubMedCrossRefGoogle Scholar
  55. 55.
    Baluk P, Raymond WW, Ator E et al. Matrix metalloproteinase-2 and-9 expression increases in mycoplasma-infected airways but is not required for microvascular remodeling. Am J Physiol Lung Cell Mol Physiol 2004; 287:1307–1317.CrossRefGoogle Scholar
  56. 56.
    Corry DB, Rishi K, Kanellis J et al. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol 2002; 3:347–353.PubMedCrossRefGoogle Scholar
  57. 57.
    Corry DB, Kiss A, Song LZ et al. Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J 2004; 18:995–997.PubMedGoogle Scholar
  58. 58.
    Lukkarinen H, Hogmalm A, Lappalainen U et al. MMP-9 deficiency worsens lung injury in a model of bronchopulmonary dysplasia. Am J Respir Cell Mol Biol 2009; 41:59–68.PubMedCrossRefGoogle Scholar
  59. 59.
    Tanaka A, Yamane Y, Matsuda H. Mast cell MMP-9 production enhanced by bacterial lipopolysaccharide. J Vet Med Sci 2001; 63:811–813.PubMedCrossRefGoogle Scholar
  60. 60.
    Fang KC, Raymond WW, Blount JL et al. Dog mast cell α-chymase activates progelatinase B by cleaving the Phe88-Phe89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem 1997; 272:25628–25635.PubMedCrossRefGoogle Scholar
  61. 61.
    Frank BT, Rossall JC, Caughey GH et al. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by α-chymase. J Immunol 2001; 166:2783–2792.PubMedGoogle Scholar
  62. 62.
    Kishi K, Muramatsu M, Jin D et al. The effects of chymase on MMP-2 activation in neointimal hyperplasia after balloon injury in dogs. Hypertens Res 2007; 30:77–83.PubMedCrossRefGoogle Scholar
  63. 63.
    Ishida K, Takai S, Murano M et al. Role of chymase-dependent MMP-9 activation in mice with dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther 2008; 324:422–426.PubMedCrossRefGoogle Scholar
  64. 64.
    Inoue N, Muramatsu M, Jin D et al. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 2009; 204:359–364.PubMedCrossRefGoogle Scholar
  65. 65.
    Rueff F, Przybilla B, Bilo MB et al. Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy: importance of baseline serum tryptase. J Allergy Clin Immunol 2009; 124:1047–1054.PubMedCrossRefGoogle Scholar
  66. 66.
    Marshall RP, Gohlke P, Chambers RC et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286:L156–L164.PubMedCrossRefGoogle Scholar
  67. 67.
    Imai Y, Kuba K, Rao S et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436:112–116.PubMedCrossRefGoogle Scholar
  68. 68.
    Reilly CF, Tewksbury DA, Schechter NB et al. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 1982; 257:8619–8622.PubMedGoogle Scholar
  69. 69.
    Wintroub BU, Schechter NB, Lazarus GS et al. Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Derm 1984; 83:336–339.PubMedCrossRefGoogle Scholar
  70. 70.
    Urata H, Kinoshita A, Misono KS et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265:22348–22357.PubMedGoogle Scholar
  71. 71.
    Urata H, Kinoshita A, Perez DM et al. Cloning of the gene and cDNA for human heart chymase. J Biol Chem 1991; 266:17173–17179.PubMedGoogle Scholar
  72. 72.
    Caughey GH, Zerweck EH, Vanderslice P. Structure, chromosomal assignment and deduced amino acid sequence of ahuman gene for mast cell chymase. J Biol Chem 1991; 266:12956–12963.PubMedGoogle Scholar
  73. 73.
    Caughey GH, Schaumberg TH, Zerweck EH et al. The human mast cell chymase gene (CMA1): mapping to the cathepsin G/granzyme gene cluster and lineage-restricted expression. Genomics 1993; 15:614–620.PubMedCrossRefGoogle Scholar
  74. 74.
    Woodbury RG, Everitt M, Sanada Y et al. A major serine protease in rat skeletal muscle: Evidence for its mast cell origin. Proc Natl Acad Sci USA 1978; 75:5311–5313.PubMedCrossRefGoogle Scholar
  75. 75.
    Woodbury RG, Neurath H. Structure, specificity and localization of the serine proteases of connective tissue. FEBS Lett 1980; 114:189–195.PubMedCrossRefGoogle Scholar
  76. 76.
    Woodbury RG, Gruzenski GM, Lagunoff D. Immunofluorescent localization of a serine protease in rat small intestine. Proc Natl Acad Sci USA 1978; 75:2785–2789.PubMedCrossRefGoogle Scholar
  77. 77.
    Schechter NM, Irani AM, Sprows JL et al. Identification of a cathepsin G-like proteinase in the mctc type of human mast cell. J Immunol 1990; 145:2652–2661.PubMedGoogle Scholar
  78. 78.
    Benyon RC, Enciso JA, Befus AD. Analysis of human skin mast cell proteins by two-dimensional gel electrophoresis: identification of tryptase as a sialylated glycoprotein. J Immunol 1993; 151:2699–2706.PubMedGoogle Scholar
  79. 79.
    de Garavilla L, Greco MN, Sukumar N et al. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem 2005; 280:18001–18007.PubMedCrossRefGoogle Scholar
  80. 80.
    Maryanoff BE, de Garavilla L, Greco MN et al. Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Respir Crit Care Med 2010; 181:247–253.PubMedCrossRefGoogle Scholar
  81. 81.
    Lundequist A, Tchougounova E, Abrink M et al. Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of angiotensin II. J Biol Chem 2004; 279:32339–32344.PubMedCrossRefGoogle Scholar
  82. 82.
    Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell α-and β-chymases. Biochim Biophys Acta 2000; 1480:245–257.PubMedCrossRefGoogle Scholar
  83. 83.
    Wei CC, Hase N, Inoue Y et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 2010.Google Scholar
  84. 84.
    Wei CC, Meng QC, Palmer R et al. Evidence for angiotensin-converting enzyme-and chymase-mediated angiotensin ii formationin the interstitial fluid space of the dog heart in vivo. Circulation 1999; 99:2583–2589.PubMedGoogle Scholar
  85. 85.
    Ju H, Gros R, You X et al. Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci USA 2001; 98:7469–7474.PubMedCrossRefGoogle Scholar
  86. 86.
    Shiota N, Okunishi H, Takai S et al. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 1999; 99:1084–1090.PubMedGoogle Scholar
  87. 87.
    Sakaguchi M, Takai S, Jin D et al. A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur J Pharmacol 2004; 493:173–176.PubMedCrossRefGoogle Scholar
  88. 88.
    Takai S, Jin D, Muramatsu M et al. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur J Pharmacol 2004; 501:1–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Mackins CJ, Kano S, Seyedi N et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release and arrhythmias in ischemia/reperfusion. J Clin Invest 2006; 116:1063–1070.PubMedCrossRefGoogle Scholar
  90. 90.
    Kano S, Tyler E, Salazar-Rodriguez M et al. Immediate hypersensitivity elicits renin release from cardiac mast cells. Int Arch Allergy Immunol 2008; 146:71–75.PubMedCrossRefGoogle Scholar
  91. 91.
    Knight PA, Wright SH, Lawrence CE et al. Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1. J Exp Med 2000; 192:1849–1856.PubMedCrossRefGoogle Scholar
  92. 92.
    Wastling JM, Scudamore CL, Thornton EM et al. Constitutive expression of mouse mast cell protease-1 in normal Balb/c mice and its up-regulation during intestinal nematode infection. Immunology 1997; 90:308–313.PubMedCrossRefGoogle Scholar
  93. 93.
    Knight PA, Wright SH, Brown JK et al. Enteric expression of the integrin αvβ6 is essential for nematode-induced mucosal mast cell hyperplasia and expression of the granule chymase, mouse mast cell protease-1. Am J Pathol 2002; 161:771–779.PubMedCrossRefGoogle Scholar
  94. 94.
    Pemberton AD, Wright SH, Knight PA et al. Anaphylactic release of mucosal mast cell granule proteases: role of serpins in the differential clearance of mouse mast cell proteases-1 and-2. J Immunol 2006; 176:899–904.PubMedGoogle Scholar
  95. 95.
    Groschwitz KR, Ahrens R, Osterfeld H et al. Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism. Proc Natl Acad Sci USA 2009; 106:22381–22386.PubMedCrossRefGoogle Scholar
  96. 96.
    Jacob C, Yang PC, Darmoul D et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of PAR-2 and beta-arrestins. J Biol Chem 2005; 280:31936–31948.PubMedCrossRefGoogle Scholar
  97. 97.
    Mellon MB, Frank BT, Fang KC. Mast cell α-chymase reduces ige recognition of birch pollen profilin by cleaving antibody-binding epitopes. J Immunol 2002; 168:290–297.PubMedGoogle Scholar
  98. 98.
    Balzar S, Chu HW, Strand M et al. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med 2005; 171:431–439.PubMedCrossRefGoogle Scholar
  99. 99.
    Waern I, Jonasson S, Hjoberg J et al. Mouse mast cell protease 4 is the major chymase in murine airways and has a protective role in allergic airway inflammation. J Immunol 2009; 183:6369–6376.PubMedCrossRefGoogle Scholar
  100. 100.
    Lazaar AL, Plotnick MI, Kucich U et al. Mast cell chymase modifies cell-matrix interactions and inhibits mitogen-induced proliferation of human airway smooth muscle cells. J Immunol 2002; 169:1014–1020.PubMedGoogle Scholar
  101. 101.
    Leskinen M, Wang Y, Leszczynski D et al. Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21:516–522.PubMedCrossRefGoogle Scholar
  102. 102.
    Leskinen MJ, Heikkila HM, Speer MY et al. Mast cell chymase induces smooth muscle cell apoptosis by disrupting nf-kappab-mediated survival signaling. Exp Cell Res 2006; 312:1289–1298.PubMedCrossRefGoogle Scholar
  103. 103.
    Sun J, Zhang J, Lindholt JS et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 2009; 120:973–982.PubMedCrossRefGoogle Scholar
  104. 104.
    McNeil HP, Adachi R, Stevens RL. Mast cell-restricted tryptases: Structure and function in inflammation and pathogen defense. J Biol Chem 2007; 282:20785–20789.PubMedCrossRefGoogle Scholar
  105. 105.
    Malaviya R, Ross E, Jakschik BA et al. Mast cell degranulation induced by type 1 fimbriated Escherichia coli in mice. J Clin Invest 1994; 93:1645–1653.PubMedCrossRefGoogle Scholar
  106. 106.
    Malaviya R, Ikeda T, Ross E et al. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNFα. Nature 1996; 381:77–80.PubMedCrossRefGoogle Scholar
  107. 107.
    Sutherland RE, Olsen JS, McKinstry A et al. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 2008; 181:5598–5605.PubMedGoogle Scholar
  108. 108.
    Huang C, Friend DS, Qiu WT et al. Induction of a selective and persistent extravasation of neutrophils into the peritoneal cavity by tryptase mouse mast cell protease 6. J Immunol 1998; 160:1910–1919.PubMedGoogle Scholar
  109. 109.
    Thakurdas SM, Melicoff E, Sansores-Garcia L et al. The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections. J Biol Chem 2007; 282:20809–20815.PubMedCrossRefGoogle Scholar
  110. 110.
    Huang C, De Sanctis GT, O’Brien PJ et al. Evaluation of the substrate specificity of human mast cell tryptase βI and demonstration of its importance in bacterial infections of the lung. J Biol Chem 2001; 276:26276–26284.PubMedCrossRefGoogle Scholar
  111. 111.
    Soto D, Malmsten C, Blount JL et al. Genetic deficiency of human mast cell α-tryptase. Clin Exp Allergy 2002; 32:1000–1006.PubMedCrossRefGoogle Scholar
  112. 112.
    Trivedi NN, Raymond WW, Caughey GH. Chimerism, point mutation and truncation dramatically transformed mast cell δ-tryptases during primate evolution. J Allergy Clin Immunol 2008;121:1262–1268.PubMedCrossRefGoogle Scholar
  113. 113.
    Trivedi NN, Tamraz B, Chu C et al. Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. J Allergy Clin Immunol 2009; 124:1099–1105.PubMedCrossRefGoogle Scholar
  114. 114.
    Schwartz LB, Atkins PC, Bradford TR et al. Release of tryptase together with histamine during the immediate cutaneous response to allergen. J Allergy Clin Immunol 1987; 80:850–855.PubMedCrossRefGoogle Scholar
  115. 115.
    Shalit M, Schwartz LB, Golzar N et al. Release of histamine and tryptase in vivo after prolonged cutaneous challenge with allergen in humans. J Pharmacol Exp Ther 1988; 244:133–137.Google Scholar
  116. 116.
    Wenzel SE, Fowler A, Schwartz LB. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. Am Rev Respir Dis 1988; 137:1002–1008.PubMedGoogle Scholar
  117. 117.
    Woodruff PG, Modrek B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388–395.PubMedCrossRefGoogle Scholar
  118. 118.
    Oh S-W, Pae CI, Lee D-K et al. Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol 2002; 168:1992–2000.PubMedGoogle Scholar
  119. 119.
    Chen CL, Wang SD, Zeng ZY et al. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 2006; 118:105–112.PubMedCrossRefGoogle Scholar
  120. 120.
    Mori S, Itoh Y, Shinohata R et al. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003; 92:420–423.PubMedCrossRefGoogle Scholar
  121. 121.
    Sommerhoff CP, Sollner C, Mentele R et al. A kazal-type inhibitor of human mast cell tryptase: isolation from the medicinal leech Hirudo medicinalis, characterization and sequence analysis. Biol Chem Hoppe-Seyler 1994; 375:685–694.PubMedCrossRefGoogle Scholar
  122. 122.
    Krishna MT, Chauhan A, Little L et al. Inhibition of mast cell tryptase by inhaled APC366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol 2001;107:1039–1045.PubMedCrossRefGoogle Scholar
  123. 123.
    Erin EM, Leaker BR, Zacharasiewicz A et al. Effects of a reversible β-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. Clin Exp Allergy 2006; 36:458–464.PubMedCrossRefGoogle Scholar
  124. 124.
    He S, Aslam A, Gaca MD et al. Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of PAR-2 on histamine release. J Pharmacol Exp Ther 2004; 309:119–126.PubMedCrossRefGoogle Scholar
  125. 125.
    He S, Gaca MD, Walls AF. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J Pharmacol Exp Ther 1998; 286:289–297.PubMedGoogle Scholar
  126. 126.
    Molinari JF, Moore WR, Clark J et al. Role of tryptase in immediate cutaneous responses in allergic sheep. J Appl Physiol 1995; 79:1966–1970.PubMedGoogle Scholar
  127. 127.
    Clark JM, Abraham WM, Fishman CE et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Resp Crit Care Med 1995; 152:2076–2083.PubMedGoogle Scholar
  128. 128.
    Wright CD, Havill AM, Middleton SC et al. Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (amg-126737). Biochem Pharmacol 1999; 58:1989–1996.PubMedCrossRefGoogle Scholar
  129. 129.
    Rice KD, Wang VR, Gangloff AR et al. Dibasic inhibitors of human mast cell tryptase. Part 2:Structure-activity relationships and requirements for potent activity. Bioorg Med Chem Lett 2000; 10:2361–2366.PubMedCrossRefGoogle Scholar
  130. 130.
    Cairns JA. Inhibitors of mast cell tryptase β as therapeutics for the treatment of asthma and inflammatory disorders. Pulm Pharmacol Ther 2005; 18:55–66.PubMedCrossRefGoogle Scholar
  131. 131.
    Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 1991; 88:493–499.PubMedCrossRefGoogle Scholar
  132. 132.
    Hartmann T, Ruoss SJ, Caughey GH. Modulation of thrombin and thrombin receptor peptide mitogenicity by human lung mast cell tryptase. Am J Physiol Lung Cell Mol Physiol 1994; 267:L113–L119.Google Scholar
  133. 133.
    Gruber BL, Kew RR, Jelaska A et al. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J Immunol 1997; 158:2310–2317.PubMedGoogle Scholar
  134. 134.
    Cairns JA, Walls AF. Mast cell tryptase stimulates synthesis of type I collagen in human lung fibroblasts. J Clin Invest 1997; 99:1313–1321.PubMedCrossRefGoogle Scholar
  135. 135.
    Brown JK, Tyler CL, Jones CA et al. Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. Am J Resp Cell Mol Biol 1995; 13:227–236.Google Scholar
  136. 136.
    Blair RJ, Meng H, Marchese MJ et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99:2691–2700.PubMedCrossRefGoogle Scholar
  137. 137.
    McNeil HP, Shin K, Campbell IK et al. The mouse mast cell-restricted tetramer-forming tryptases mMCP6 and mMCP7 are critical mediators in inflammatory arthritis. Arthritis Rheum 2008; 58:2338–2346.PubMedCrossRefGoogle Scholar
  138. 138.
    Shin K, Nigrovic PA, Crish J et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009; 182:647–656.PubMedGoogle Scholar
  139. 139.
    Buckley MG, Walters C, Wong WM et al. Mast cell activation in arthritis: detection of α-and β-tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci (Colch) 1997; 93:363–370.Google Scholar
  140. 140.
    Lee DM, Friend DS, Gurish MF et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297:1689–1692.PubMedCrossRefGoogle Scholar
  141. 141.
    Nigrovic PA, Binstadt BA, Monach PA et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci USA 2007; 104:2325–2330.PubMedCrossRefGoogle Scholar
  142. 142.
    Nigrovic PA, Lee DM. Synovial mast cells: role in acute and chronic arthritis. Immunol Rev 2007; 217:19–37.PubMedCrossRefGoogle Scholar
  143. 143.
    Zhou JS, Xing W, Friend DS et al. Mast cell deficiency in KitW-sh mice does not impair antibody-mediated arthritis. J Exp Med 2007; 204:2797–2802PubMedCrossRefGoogle Scholar
  144. 144.
    Balázs M, Illyés G, Vadász G. Mast cells in ulcerative colitis. Quantitative and ultrastructural studies. Virchows Arch 1989; 57:353–360.CrossRefGoogle Scholar
  145. 145.
    Fox CC, Lazenby AJ, Moore WC et al. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990; 99:119–124.PubMedGoogle Scholar
  146. 146.
    Tremaine WJ, Brzezinski A, Katz JA et al. Treatment of mildly to moderately active ulcerative colitis with atryptase inhibitor (APC2059): an open-label pilot study. Aliment Pharmacol Ther 2002; 16:407–413.PubMedCrossRefGoogle Scholar
  147. 147.
    Isozaki Y, Yoshida N, Kuroda M et al. Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis. Scand J Gastroenterol 2006; 41:944–953.PubMedCrossRefGoogle Scholar
  148. 148.
    Rubinstein I, Nadel JA, Graf PD et al. Mast cell chymase potentiates histamine-induced wheal formation in the skin of ragweed-allergic dogs. J Clin Invest 1990; 86:555–559.PubMedCrossRefGoogle Scholar
  149. 149.
    Briggaman RA, Schechter NM, Fraki J et al. Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes. J Exp Med 1984; 160:1027–1042.PubMedCrossRefGoogle Scholar
  150. 150.
    Sommerhoff CP, Caughey GH, Finkbeiner WE et al. Mast cell chymase. A potent secretagogue for airway gland serous cells. J Immunol 1989; 142:2450–2456.PubMedGoogle Scholar
  151. 151.
    Sommerhoff CP, Nadel JA, Basbaum CB et al. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990; 85:682–689.PubMedCrossRefGoogle Scholar
  152. 152.
    Matin R, Tam EK, Nadel JA et al. Distribution of chymase-containing mast cells in human bronchi. J Histochem Cytochem 1992; 40:781–786.PubMedCrossRefGoogle Scholar
  153. 153.
    Raymond WW, Waugh Ruggles S, Craik CS et al. Albumin is a substrate of human chymase: prediction by combinatorial peptide screening and development of a selective inhibitor based on the albumin cleavage site. J Biol Chem 2003; 278:34517–34524.PubMedCrossRefGoogle Scholar
  154. 154.
    Muramatsu M, Katada J, Hattori M et al. Chymase mediates mast cell-induced angiogenesis in hamster sponge granulomas. Eur J Pharmacol 2000; 402:181–191.PubMedCrossRefGoogle Scholar
  155. 155.
    Abonia JP, Friend DS, Austen WG Jr et al. Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle. J Immunol 2005; 174:7285–7291.PubMedGoogle Scholar
  156. 156.
    Sun J, Sukhova GK, Yang M et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117:3359–3368.PubMedCrossRefGoogle Scholar
  157. 157.
    Shiota N, Fukamizu A, Takai S et al. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J Hypertens 1997; 15:431–440.PubMedCrossRefGoogle Scholar
  158. 158.
    Takai S, Shiota N, Kobayashi S et al. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997; 412:86–90.PubMedCrossRefGoogle Scholar
  159. 159.
    Takai S, Yuda A, Jin D et al. Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett 2000; 467:141–144.PubMedCrossRefGoogle Scholar
  160. 160.
    Nishimoto M, Takai S, Kim S et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 2001; 104:1274–1279.PubMedCrossRefGoogle Scholar
  161. 161.
    Wolters PJ, Laig-Webster M, Caughey GH. Dipeptidyl peptidase I cleaves matrix-associated proteins and is expressed mainly by mast cells in normal dog airways. Am J Respir Cell Mol Biol 2000; 22:183–190.PubMedGoogle Scholar
  162. 162.
    Wolters PJ, Raymond WW, Blount JL et al. Regulated expression, processing and secretion of dog mast cell dipeptidyl peptidase I. J Biol Chem 1998; 273:15514–15520.PubMedCrossRefGoogle Scholar
  163. 163.
    Turk D, Janjic V, Stern I et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J 2001; 20:6570–6582.PubMedCrossRefGoogle Scholar
  164. 164.
    McGuire MJ, Lipsky PE, Thiele DL. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J Biol Chem 1993; 268:2458–2467.PubMedGoogle Scholar
  165. 165.
    Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci USA 1999; 96:8627–8632.PubMedCrossRefGoogle Scholar
  166. 166.
    Wolters PJ, Pham CT, Muilenburg DJ et al. Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem 2001; 276:18551–18556.PubMedCrossRefGoogle Scholar
  167. 167.
    Caughey GH. A pulmonary perspective on GASPIDs: Granule-associated serine peptidases of immune defense. Curr Resp Med Rev 2006; 2:263–277.Google Scholar
  168. 168.
    Adkison AM, Raptis SZ, Kelley DG et al. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002; 109:363–371.PubMedGoogle Scholar
  169. 169.
    Pham CT, Ivanovich JL, Raptis SZ et al. Papillon-Lefevre syndrome: correlating the molecular, cellular and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J Immunol 2004; 173:7277–7281.PubMedGoogle Scholar
  170. 170.
    Vanderslice P, Ballinger SM, Tam EK et al. Human mast cell tryptase: multiple cDNAs and genes reveal amultigene serine protease family. Proc Natl Acad Sci USA 1990; 87:3811–3815.PubMedCrossRefGoogle Scholar
  171. 171.
    Vanderslice P, Craik CS, Nadel JA et al. Molecular cloning of dog mast cell tryptase and a related protease: structural evidence of aunique mode of serine protease activation. Biochemistry 1989; 28:4148–4155.PubMedCrossRefGoogle Scholar
  172. 172.
    Sakai K, Ren S, Schwartz LB. A novel heparin-dependent processing pathway for human tryptase: autocatalysis followed by activation with dipeptidyl peptidase I. J Clin Invest 1996; 97:988–995.PubMedCrossRefGoogle Scholar
  173. 173.
    Henningsson F, Yamamoto K, Saftig P et al. A role for cathepsin E in the processing of mast-cell carboxypeptidase A. J Cell Sci 2005; 118:2035–2042.PubMedCrossRefGoogle Scholar
  174. 174.
    Henningsson F, Wolters P, Chapman HA et al. Mast cell cathepsins C and S control levels of carboxypeptidase A and the chymase, mouse mast cell protease 5. Biol Chem 2003; 384:1527–1531.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2011

Authors and Affiliations

  • George H. Caughey
    • 1
  1. 1.Department of MedicineUniversity of California at San FranciscoSan FranciscoUSA

Personalised recommendations